What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy (CAV), is one of the major causes of mortality late after transplantation. It affects up to 50% of all heart transplant recipients within 5 years of surgery. The mechanisms of CAV are multifactorial and i...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2000
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59623/ |